{"id":33553,"date":"2025-09-30T16:51:35","date_gmt":"2025-09-30T11:21:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33553"},"modified":"2025-09-30T16:51:39","modified_gmt":"2025-09-30T11:21:39","slug":"pharma-news-for-regeneron-kedrion-crinetics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics","title":{"rendered":"Regeneron\u2019s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year; Eli Lilly\u2019s INLURIYO Approved for ER+, HER2-, ESR1-Mutated Advanced Breast Cancer; Janssen\u2019s TREMFYA Secures FDA Nod for Pediatric Plaque Psoriasis and Psoriatic Arthritis; Kedrion Biopharma\u2019s QIVIGY Approved for Primary Humoral Immunodeficiency in Adults; Crinetics Pharma Wins FDA Approval for First Daily Pill, PALSONIFY, for Rare Growth Disorder"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a07bda207db1\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a07bda207db1\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\/#Regenerons_EVKEEZA_Wins_FDA_Approval_for_HoFH_in_Children_as_Young_as_1_Year\" >Regeneron\u2019s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\/#FDA_Approves_Eli_Lillys_INLURIYO_for_ER_HER2-_ESR1-Mutated_Advanced_Breast_Cancer\" >FDA Approves Eli Lilly\u2019s INLURIYO for ER+, HER2-, ESR1-Mutated Advanced Breast Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\/#Janssens_TREMFYA_Secures_FDA_Nod_for_Pediatric_Plaque_Psoriasis_and_Psoriatic_Arthritis\" >Janssen\u2019s TREMFYA Secures FDA Nod for Pediatric Plaque Psoriasis and Psoriatic Arthritis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\/#Kedrion_Biopharmas_QIVIGY_Immune_Globulin_10_IV_Approved_by_FDA_for_Primary_Humoral_Immunodeficiency_in_Adults\" >Kedrion Biopharma\u2019s QIVIGY (Immune Globulin 10% IV) Approved by FDA for Primary Humoral Immunodeficiency in Adults<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\/#FDA_Approves_Crinetics_Pharmas_First_Daily_Pill_PALSONIFY_for_Rare_Growth_Disorder\" >FDA Approves Crinetics Pharma\u2019s First Daily Pill, PALSONIFY, for Rare Growth Disorder<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-regeneron-s-evkeeza-wins-fda-approval-for-hofh-in-children-as-young-as-1-year\"><span class=\"ez-toc-section\" id=\"Regenerons_EVKEEZA_Wins_FDA_Approval_for_HoFH_in_Children_as_Young_as_1_Year\"><\/span>Regeneron\u2019s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Regeneron Pharmaceuticals, Inc.<\/strong> announced that the FDA has approved <strong>EVKEEZA (evinacumab-dgnb)<\/strong> ANGPTL3 antibody, for children aged 1 to under 5 years with <a href=\"https:\/\/www.delveinsight.com\/report-store\/homozygous-familial-hypercholesterolemia-market\">homozygous familial hypercholesterolemia (HoFH)<\/a>. This expands the indication from its previous approval for children aged 5\u201311 and adolescents and adults aged 12 and older. EVKEEZA is approved as an adjunct to diet, exercise, and other lipid-lowering therapies.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe approval of EVKEEZA for children as young as 1 year addresses a critical unmet need for those with HoFH, a life-threatening condition causing extremely high LDL-C levels from birth,\u201d said <\/em><strong><em>Katherine Wilemon, Founder and CEO of the Family Heart Foundation<\/em><\/strong><em>. \u201cFamilies and their medical teams now have an effective treatment option for these very young patients at risk of serious cardiovascular complications.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>HoFH is a rare genetic disorder affecting approximately 1,300 people in the U.S., resulting in LDL-C levels often exceeding 400 mg\/dL. Patients are at risk of premature atherosclerotic disease and cardiac events, sometimes during their teenage years. EVKEEZA\u2019s initial approval in 2021 was based on a placebo-controlled trial showing about 50% LDL-C reduction when added to standard lipid-lowering therapies. The extended indication was supported by clinical efficacy and safety data from 6 children treated under expanded access or compassionate use programs, with no new safety concerns identified.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cEVKEEZA is a testament to the power of Regeneron\u2019s science and proprietary technologies in developing first-in-class, life-changing medicines,\u201d said <\/em><strong><em>George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and CSO at Regeneron<\/em><\/strong><em>. \u201cThis label extension reinforces our commitment to rare diseases, including neuromuscular and genetic disorders, where we continue to advance innovative therapies.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-eli-lilly-s-inluriyo-for-er-her2-esr1-mutated-advanced-breast-cancer\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Eli_Lillys_INLURIYO_for_ER_HER2-_ESR1-Mutated_Advanced_Breast_Cancer\"><\/span>FDA Approves Eli Lilly\u2019s INLURIYO for ER+, HER2-, ESR1-Mutated Advanced Breast Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Eli Lilly and Company<\/strong> announced that the FDA has approved <strong>INLURIYO (imlunestrant, 200 mg tablets)<\/strong> for adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-market\">estrogen receptor-positive (ER+), HER2-negative<\/a>,<a href=\"https:\/\/www.delveinsight.com\/report-store\/esr1-mutated-metastatic-breast-cancer-market\"> ESR1-mutated advanced or metastatic breast cancer (MBC)<\/a> whose disease progressed after at least one line of endocrine therapy. INLURIYO is a once-daily oral estrogen receptor antagonist designed to block and degrade overactive estrogen receptors, slowing tumor progression.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;This therapy reflects our commitment to developing treatments that improve outcomes for people with breast cancer and represents an important step toward advancing innovative, all-oral treatment approaches,&#8221; said <\/em><strong><em>Jacob Van Naarden, EVP and President of Lilly Oncology<\/em><\/strong><em>. &#8220;We are deeply grateful to the patients, investigators, Lilly team members, and clinical care teams who made this advancement possible.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA approval is based on the Phase III EMBER-3 trial, in which INLURIYO reduced the risk of progression or death by 38% versus standard endocrine therapy in patients with ESR1-mutated MBC. Median progression-free survival was 5.5 months versus 3.8 months for fulvestrant or exemestane (HR=0.62, p=0.0008). Adverse events were mostly low grade, with 4.6% of patients discontinuing due to side effects.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;This represents an important advancement for patients with ESR1-mutated MBC, a mutation found in nearly half of those previously treated with hormone therapies,&#8221; said <\/em><strong><em>Komal Jhaveri, M.D., FACP, FASCO, Memorial Sloan Kettering Cancer Center<\/em><\/strong><em>. &#8220;With its efficacy, tolerability, and oral administration, INLURIYO provides a meaningful alternative treatment option for this patient population.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-janssen-s-tremfya-secures-fda-nod-for-pediatric-plaque-psoriasis-and-psoriatic-arthritis\"><span class=\"ez-toc-section\" id=\"Janssens_TREMFYA_Secures_FDA_Nod_for_Pediatric_Plaque_Psoriasis_and_Psoriatic_Arthritis\"><\/span>Janssen\u2019s TREMFYA Secures FDA Nod for Pediatric Plaque Psoriasis and Psoriatic Arthritis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Johnson &amp; Johnson <\/strong>announced that the FDA has approved <strong>TREMFYA (guselkumab)<\/strong> for children aged six years and older, weighing at least 40 kg, with <a href=\"https:\/\/www.delveinsight.com\/report-store\/plaque-psoriasis-market\">moderate to severe plaque psoriasis (PsO)<\/a> or <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-market\">active psoriatic arthritis (PsA)<\/a>. This milestone makes TREMFYA the first and only IL-23 inhibitor approved for these pediatric indications, expanding upon its earlier adult approvals for PsO in 2017 and PsA in 2020.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cDespite advancements in treatment, there continues to be a significant gap in therapies for children living with these debilitating immune-mediated diseases,\u201d said <\/em><strong><em>Vimal Hasmukh Prajapati, M.D., University of Calgary and Co-Director of the Skin Health &amp; Wellness Centre<\/em><\/strong><em>. \u201cTREMFYA offers physicians and families an established option with proven safety and efficacy to improve symptoms and quality of life.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The plaque PsO approval was supported by the Phase III PROTOSTAR study, where TREMFYA achieved co-primary endpoints of PASI 90 and IGA 0\/1 at Week 16. Approximately 56% of patients reached PASI 90 versus 16% on placebo, and nearly 40% achieved complete clearance (IGA 0). The active PsA indication was supported by pharmacokinetic extrapolation from adult PsO and PsA studies, confirming safety and efficacy in pediatric patients.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cEvery child deserves to be active without limitations from joint pain or skin symptoms,\u201d said <\/em><strong><em>Brandee Pappalardo, PhD, MPH, VP, Medical Affairs, Dermatology &amp; Rheumatology, J&amp;J Innovative Medicine<\/em><\/strong><em>. \u201cThe approval of TREMFYA\u2019s pediatric indications represents a meaningful step forward for children and their care partners, reflecting our commitment to chronic immune-mediated disease research.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>TREMFYA is administered subcutaneously at Week 0, Week 4, and every 8 weeks thereafter, with a recommended dose of 100 mg for eligible pediatric patients. This approval underscores Johnson &amp; Johnson\u2019s ongoing dedication to advancing treatments for chronic immune-mediated diseases in both adult and pediatric populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-kedrion-biopharma-s-qivigy-immune-globulin-10-iv-approved-by-fda-for-primary-humoral-immunodeficiency-in-adults\"><span class=\"ez-toc-section\" id=\"Kedrion_Biopharmas_QIVIGY_Immune_Globulin_10_IV_Approved_by_FDA_for_Primary_Humoral_Immunodeficiency_in_Adults\"><\/span>Kedrion Biopharma\u2019s QIVIGY (Immune Globulin 10% IV) Approved by FDA for Primary Humoral Immunodeficiency in Adults<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Kedrion Biopharma<\/strong> announced that the FDA has approved <strong>QIVIGY (immune globulin intravenous [human]-kthm 10% liquid)<\/strong> for adults with primary humoral immunodeficiency (PI), a group of rare disorders that compromise the immune system. QIVIGY, developed and manufactured exclusively by Kedrion in the U.S. and Italy, addresses the unmet needs of patients living with PI and joins Kedrion\u2019s expanding global portfolio of therapies.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cSeeing QIVIGY receive FDA approval is a deeply meaningful moment for all of us at Kedrion,\u201d said <\/em><strong><em>Ugo Di Francesco, CEO, Kedrion<\/em><\/strong><em>. \u201cIt reflects our scientific capabilities and our mission to serve patients. Today, we celebrate a product that improves patient care while demonstrating our organization\u2019s ability to deliver.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The FDA approval was supported by a 12-month clinical study in adults with PI, where QIVIGY met its primary endpoint with no acute serious bacterial infections. Secondary outcomes showed a low rate of other infections, no infection-related hospitalizations, and minimal disruption to daily life.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Common adverse events included headache, infusion reactions, fatigue, and nausea. \u201cFor individuals living with PI, fewer infections mean less disruption to daily life, highlighting our commitment to therapies that support patients\u2019 health and well-being,\u201d said <\/em><strong><em>Nisha Jain, VP, Global Clinical Development, Kedrion<\/em><\/strong><em>.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>QIVIGY represents a strategic milestone for Kedrion, reflecting long-term investments in manufacturing, plasma collection, and R&amp;D to expand rare disease treatments.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201c2025 has been transformative for Kedrion, and QIVIGY marks a pivotal accomplishment as we continue to expand in the U.S. and globally,\u201d said <\/em><strong><em>Bob Rossilli, Global Chief Commercial Officer, Kedrion<\/em><\/strong><em>.&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>QIVIGY will be launched in the U.S. first, with availability expected in early 2026, and plans for expansion into Europe and other markets upon approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-crinetics-pharma-s-first-daily-pill-palsonify-for-rare-growth-disorder\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Crinetics_Pharmas_First_Daily_Pill_PALSONIFY_for_Rare_Growth_Disorder\"><\/span>FDA Approves Crinetics Pharma\u2019s First Daily Pill, PALSONIFY, for Rare Growth Disorder<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has approved <strong>PALSONIFY (paltusotine)<\/strong> from <strong>Crinetics Pharmaceuticals<\/strong> for first-line <a href=\"https:\/\/www.delveinsight.com\/report-store\/acromegaly-market\">treatment of adults with acromegaly<\/a> who have an inadequate response to surgery or for whom surgery is not an option. PALSONIFY is the first once-daily, oral treatment for acromegaly, offering a convenient alternative to injectable therapies for this rare disorder, which is characterized by excessive growth hormone and abnormal enlargement of hands, feet, and facial features.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPALSONIFY represents a major advancement for adults living with acromegaly, providing rapid, sustained biochemical control and meaningful improvements in daily symptoms,\u201d said <\/em><strong><em>Joseph Perez, MD, Chief Medical Officer, Crinetics Pharmaceuticals<\/em><\/strong><em>. \u201cWe are proud to offer patients an oral therapy that can help improve their quality of life while addressing a critical unmet medical need.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval was based on results from the Phase III PATHFNDR-1 and PATHFNDR-2 trials, which demonstrated PALSONIFY\u2019s consistent efficacy in both previously treated and medically untreated adults. Participants reported significant reductions in signs and symptoms, including headaches, joint pain, sweating, fatigue, and swelling, as measured by the FDA-aligned Acromegaly Symptom Diary (ASD). PALSONIFY was generally well-tolerated, with no serious adverse events reported in the randomized controlled portions of the studies.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cOral administration of PALSONIFY is a game-changer for patients, reducing the treatment burden while maintaining effective disease control,\u201d said <\/em><strong><em>Sarah Thompson, VP of Clinical Development, Crinetics Pharmaceuticals<\/em><\/strong><em>. PALSONIFY is expected to be available in the U.S. in early October. Global expansion plans are underway, including a Marketing Authorization Application under review in the European Union and a partnership with Sanwa Kagaku Kenkyuso (SKK) for development in Japan. The therapy is also being evaluated in Phase III trials for carcinoid syndrome.<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron\u2019s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year Regeneron Pharmaceuticals, Inc. announced that the FDA has approved EVKEEZA (evinacumab-dgnb) ANGPTL3 antibody, for children aged 1 to under 5 years with homozygous familial hypercholesterolemia (HoFH). This expands the indication from its previous approval for children aged 5\u201311 and adolescents and [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":33554,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[839,2539,127,3878,19299,204,643,704,17095,21220,21222,21221,2018,349,21382,420,639,1546,20564,22719,5789],"industry":[17225],"therapeutic_areas":[17237,17240,17227,17228,17234],"class_list":["post-33553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acromegaly","tag-acromegaly-market","tag-breast-cancer","tag-breast-cancer-treatment","tag-breast-cancers","tag-delveinsight","tag-er-positive-breast-cancer-report","tag-fda","tag-her2-negative-breast-cancer","tag-homozygous-familial-hypercholesterolemia","tag-homozygous-familial-hypercholesterolemia-market","tag-homozygous-familial-hypercholesterolemia-treatment","tag-hr-her2-advanced-breast-cancer","tag-latest-pharma-news","tag-moderate-to-severe-plaque-psoriasis","tag-news","tag-pharma-news","tag-plaque-psoriasis","tag-plaque-psoriasis-clinical-trials","tag-primary-humoral-immunodeficiency","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Regeneron, Kedrion, Crinetics<\/title>\n<meta name=\"description\" content=\"Pharma news for Regeneron\u2019s EVKEEZA; Eli Lilly\u2019s INLURIYO; Janssen\u2019s TREMFYA; Kedrion Biopharma\u2019s QIVIGY; Crinetics Pharma\u2019s PALSONIFY\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Regeneron, Kedrion, Crinetics\" \/>\n<meta property=\"og:description\" content=\"Pharma news for Regeneron\u2019s EVKEEZA; Eli Lilly\u2019s INLURIYO; Janssen\u2019s TREMFYA; Kedrion Biopharma\u2019s QIVIGY; Crinetics Pharma\u2019s PALSONIFY\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-30T11:21:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-30T11:21:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/30164628\/30-09-2025-feature.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Regeneron, Kedrion, Crinetics","description":"Pharma news for Regeneron\u2019s EVKEEZA; Eli Lilly\u2019s INLURIYO; Janssen\u2019s TREMFYA; Kedrion Biopharma\u2019s QIVIGY; Crinetics Pharma\u2019s PALSONIFY","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Regeneron, Kedrion, Crinetics","og_description":"Pharma news for Regeneron\u2019s EVKEEZA; Eli Lilly\u2019s INLURIYO; Janssen\u2019s TREMFYA; Kedrion Biopharma\u2019s QIVIGY; Crinetics Pharma\u2019s PALSONIFY","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-09-30T11:21:35+00:00","article_modified_time":"2025-09-30T11:21:39+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/30164628\/30-09-2025-feature.webp","type":"image\/webp"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics","name":"Pharma News | Regeneron, Kedrion, Crinetics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/30164628\/30-09-2025-feature.webp","datePublished":"2025-09-30T11:21:35+00:00","dateModified":"2025-09-30T11:21:39+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Pharma news for Regeneron\u2019s EVKEEZA; Eli Lilly\u2019s INLURIYO; Janssen\u2019s TREMFYA; Kedrion Biopharma\u2019s QIVIGY; Crinetics Pharma\u2019s PALSONIFY","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-regeneron-kedrion-crinetics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/30164628\/30-09-2025-feature.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/30164628\/30-09-2025-feature.webp","width":772,"height":482,"caption":"pharma-news-for-regeneron-kedrion-crinetics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/09\/30164628\/30-09-2025-feature-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acromegaly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acromegaly market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">breast cancer treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">breast cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ER positive breast cancer report<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HER2 Negative Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Homozygous Familial Hypercholesterolemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Homozygous Familial Hypercholesterolemia Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Homozygous Familial Hypercholesterolemia Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HR+\/HER2- advanced breast cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Moderate to Severe Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plaque psoriasis clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">primary humoral immunodeficiency<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acromegaly<\/span>","<span class=\"advgb-post-tax-term\">acromegaly market<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">breast cancer treatment<\/span>","<span class=\"advgb-post-tax-term\">breast cancers<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">ER positive breast cancer report<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">HER2 Negative Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Homozygous Familial Hypercholesterolemia<\/span>","<span class=\"advgb-post-tax-term\">Homozygous Familial Hypercholesterolemia Market<\/span>","<span class=\"advgb-post-tax-term\">Homozygous Familial Hypercholesterolemia Treatment<\/span>","<span class=\"advgb-post-tax-term\">HR+\/HER2- advanced breast cancer<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Moderate to Severe Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Plaque psoriasis clinical trials<\/span>","<span class=\"advgb-post-tax-term\">primary humoral immunodeficiency<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 months ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Sep 30, 2025","modified":"Updated on Sep 30, 2025"},"absolute_dates_time":{"created":"Posted on Sep 30, 2025 4:51 pm","modified":"Updated on Sep 30, 2025 4:51 pm"},"featured_img_caption":"pharma-news-for-regeneron-kedrion-crinetics\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33553"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33553\/revisions"}],"predecessor-version":[{"id":33555,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33553\/revisions\/33555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33554"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33553"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33553"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}